Bank of New York Mellon Corp Decreases Stock Holdings in Smith & Nephew SNATS, Inc. (NYSE:SNN)

Bank of New York Mellon Corp decreased its position in shares of Smith & Nephew SNATS, Inc. (NYSE:SNN - Free Report) by 90.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,617 shares of the medical equipment provider's stock after selling 160,866 shares during the period. Bank of New York Mellon Corp's holdings in Smith & Nephew SNATS were worth $471,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of SNN. National Bank of Canada FI increased its stake in shares of Smith & Nephew SNATS by 36.5% in the fourth quarter. National Bank of Canada FI now owns 1,667 shares of the medical equipment provider's stock worth $41,000 after buying an additional 446 shares during the last quarter. Bessemer Group Inc. lifted its position in shares of Smith & Nephew SNATS by 3,471.4% in the first quarter. Bessemer Group Inc. now owns 1,750 shares of the medical equipment provider's stock worth $49,000 after buying an additional 1,701 shares during the last quarter. Hara Capital LLC boosted its stake in Smith & Nephew SNATS by 391.4% during the fourth quarter. Hara Capital LLC now owns 2,457 shares of the medical equipment provider's stock worth $60,000 after buying an additional 1,957 shares in the last quarter. Opal Wealth Advisors LLC acquired a new position in shares of Smith & Nephew SNATS during the first quarter worth approximately $73,000. Finally, GAMMA Investing LLC raised its holdings in Smith & Nephew SNATS by 22.4% in the first quarter. GAMMA Investing LLC now owns 3,641 shares of the medical equipment provider's stock worth $103,000 after purchasing an additional 666 shares during the period. Hedge funds and other institutional investors own 25.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on SNN shares. Hsbc Global Res cut shares of Smith & Nephew SNATS from a "strong-buy" rating to a "hold" rating in a research report on Friday, April 25th. Canaccord Genuity Group lifted their price objective on shares of Smith & Nephew SNATS from $27.00 to $28.00 and gave the company a "hold" rating in a report on Thursday, May 1st. Finally, HSBC cut Smith & Nephew SNATS from a "buy" rating to a "hold" rating in a research note on Friday, April 25th. Six equities research analysts have rated the stock with a hold rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Smith & Nephew SNATS has an average rating of "Hold" and a consensus target price of $28.00.

Smith & Nephew SNATS Stock Up 1.0%

SNN stock traded up $0.37 on Thursday, reaching $35.87. 1,057,949 shares of the company traded hands, compared to its average volume of 900,360. The firm has a fifty day simple moving average of $30.28 and a 200-day simple moving average of $28.29. The company has a market cap of $15.71 billion, a P/E ratio of 16.60, a price-to-earnings-growth ratio of 1.08 and a beta of 0.68. Smith & Nephew SNATS, Inc. has a one year low of $23.69 and a one year high of $36.56. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.89 and a quick ratio of 1.33.

Smith & Nephew SNATS Cuts Dividend

The firm also recently disclosed a semi-annual dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 3rd will be paid a $0.285 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a dividend yield of 210.0%. Smith & Nephew SNATS's dividend payout ratio is 26.39%.

Smith & Nephew SNATS Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.